ArticlePloS one2026
Skin-related adverse events and their associated factors among Diabetic patients on insulin therapy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regenerative Therapies for Cosmetic Dermatology for Patients with Diabetes Mellitus: Skin Aging, Aesthetic Concerns, and Evidence-Based Best Practices.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMore than 530 million individuals globally are afflicted with diabetes mellitus (DM), and the prevalence continues to escalate. Insulin remains the cornerstone of DM management across the globe. Nevertheless, existing literature indicates that individuals utilizing insulin are susceptible to developing abscesses and scar formation at injection sites. These complications may undermine therapeutic adherence, thereby adversely impacting the intended clinical outcomes. This study aimed to evaluate the prevalence of abscesses and scar formation at injection sites, along with their associated factors, among diabetic patients undergoing insulin therapy in Dar es Salaam, Tanzania.
methodsA hospital-based analytical cross-sectional study was conducted from the 28th of February 2024 to the 25th of May 2024. A total of 428 patients diagnosed with diabetes mellitus and undergoing insulin therapy were enrolled from four selected hospitals in Dar es Salaam. A validated case report form (CRF) was employed to gather socio-demographic characteristics and clinical data pertinent to the formation of abscesses and scars following insulin therapy. Data were analyzed utilizing Stata version 15.0 software, with findings summarized as frequencies and percentages. Factors associated with the development of abscesses and scarring were evaluated using modified Poisson regression, and a p-value of less than 0.05 was deemed statistically significant.
resultsOf 428 participants, the prevalence of abscesses and scar formation at the insulin injection site was 22.2% and 46.7%, respectively. Factors positively associated with abscesses were improper injection technique (adjusted Prevalence Ratio [aPR] = 1.11; 95% CI: 1.02-1.21, p = 0.009) and poor injection site rotation (aPR = 2.7; 95% CI: 1.13-6.45, p = 0.025). In contrast, the use of an insulin pen was negatively associated with abscesses (aPR = 0.13; 95% CI: 0.04-0.48, p = 0.002). Scar formation was positively associated with improper injection site rotation (aPR = 1.63; 95% CI: 1.03-2.32, p = 0.037) and uncontrolled blood glucose levels (aPR = 1.69; 95% CI: 1.01-2.84, p = 0.049).
conclusionThis study indicates that skin complications at insulin injection sites are highly prevalent. The findings suggest that improper injection technique, poor site rotation, and uncontrolled blood glucose are significant modifiable risk factors. The use of insulin pens may help reduce the risk of abscesses. Therefore, targeted patient education on correct injection practices and glycemic control is crucial to minimize these complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.